Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Raises $186 Million for CAR-T Portfolio

publication date: Nov 2, 2020

CARsgen Therapeutics of Shanghai raised $186 million in a Series C round to develop its portfolio of CAR-T cell therapies. The company has developed 10 CAR-T candidates for different targets. It has started clinical trials for five of them, three in solid tumors and two in hematologic malignancies. In March, CARsgen completed a $60 million Pre-C financing and said it would use the funds to restructure and file for an "overseas" IPO in the near future. The C funding was led by Loyal Valley Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital